A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice

Vaccine

Volumn 32, Issue 34, 2014, Pages 4296-4303

  Ku, Zhiqiang ^a   Liu, Qingwei ^a   Ye, Xiaohua ^a   Cai, Yicun ^a   Wang, Xiaoli ^a   Shi, Jinping ^a   Li, Dapeng ^a   Jin, Xia ^a   An, Wenqi ^b   Huang, Zhong ^a  

^a INSTITUTE PASTEUR OF SHANGHAI   (China)

^b Hualan Biological Bacterin Company   (China)

Author keywords

Coxsackievirus A16; Enterovirus 71; Neutralizing antibody; Vaccine; Virus like particle

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS VACCINE; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS A; ENTEROVIRUS 71; FEMALE; HAND FOOT AND MOUTH DISEASE; IMMUNITY; IMMUNOGENICITY; MIXED INFECTION; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SERUM; VIRUS INFECTION; VIRUS LIKE AGENT; ANIMAL; ANTIBODY PRODUCTION; BLOOD; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; ENTEROVIRUS INFECTIONS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; NEWBORN; SERODIAGNOSIS;

ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; FEMALE; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION, PASSIVE; MICE, INBRED ICR; NEUTRALIZATION TESTS; VACCINES, VIRUS-LIKE PARTICLE; VIRAL VACCINES;

EID: 84903819994     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.025     Document Type: Article

References (47)

1. Wong S.S., Yip C.C., Lau S.K., Yuen K.Y. Human enterovirus 71 and hand, foot and mouth disease. Epidemiol Infect 2010, 138(8):1071-1089.
2. Chang L.Y., Lin T.Y., Huang Y.C., Tsao K.C., Shih S.R., Kuo M.L., et al. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999, 18(12):1092-1096.
3. Hosoya M., Kawasaki Y., Sato M., Honzumi K., Hayashi A., Hiroshima T., et al. Genetic diversity of coxsackievirus A16 associated with hand, foot, and mouth disease epidemics in Japan from 1983 to 2003. J Clin Microbiol 2007, 45(1):112-120.
4. Iwai M., Masaki A., Hasegawa S., Obara M., Horimoto E., Nakamura K., et al. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Jpn J Infect Dis 2009, 62(4):254-259.
5. Ang L.W., Koh B.K., Chan K.P., Chua L.T., James L., Goh K.T. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009, 38(2):106-112.
6. McMinn P.C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 2002, 26(1):91-107.
7. Liu F., Liu Q., Cai Y., Leng Q., Huang Z. Construction and characterization of an infectious clone of coxsackievirus A16. Virol J 2011, 8:534.
8. Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010, 10(11):778-790.
9. Lee T.C., Guo H.R., Su H.J., Yang Y.C., Chang H.L., Chen K.T. Diseases caused by enterovirus 71 infection. Pediatr Infect Dis J 2009, 28(10):904-910.
10. Xu J., Qian Y., Wang S., Serrano J.M., Li W., Huang Z., et al. EV71: an emerging infectious disease vaccine target in the Far East?. Vaccine 2010, 28(20):3516-3521.
11. Lee M.S., Chang L.Y. Development of enterovirus 71 vaccines. Expert Rev Vaccines 2010, 9(2):149-156.
12. Liang Z., Mao Q., Gao F., Wang J. Progress on the research and development of human enterovirus 71 (EV71) vaccines. Front Med 2013, 7(1):111-121.
13. Pan H., Zhu Y.F., Qi X., Zhang Y.J., Li L., Deng F., et al. [Analysis on the epidemiological and genetic characteristics of enterovirus type 71 and Coxsackie A16 virus infection in Jiangsu, China]. Zhonghua Liu Xing Bing Xue Za Zhi 2009, 30(4):339-343.
14. Zhang H.M., Li C.R., Liu Y.J., Liu W.L., Fu D., Xu L.M., et al. [To investigate pathogen of hand, foot and mouth disease in Shenzhen in 2008]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2009, 23(5):334-336.
15. Wright H.T., Landing B.H., Lennette E.H., Mc A.R. Fatal infection in an infant associated with Coxsackie virus group A, type 16. N Engl J Med 1963, 268:1041-1044.
16. Goldberg M.F., McAdams A.J. Myocarditis possibly due to Coxsackie group A, type 16, virus. J Pediatr 1963, 62:762-765.
17. Wang C.Y., Lu F.L., Wu M.H., Lee C.Y., Huang L.M. Fatal coxsackievirus A16 infection. Pediatr Infect Dis J 2004, 23(3):275-276.
18. Legay F., Leveque N., Gacouin A., Tattevin P., Bouet J., Thomas R., et al. Fatal coxsackievirus A-16 pneumonitis in adult. Emerg Infect Dis 2007, 13(7):1084-1086.
19. Goto K., Sanefuji M., Kusuhara K., Nishimura Y., Shimizu H., Kira R., et al. Rhombencephalitis and coxsackievirus A16. Emerg Infect Dis 2009, 15(10):1689-1691.
20. Xu W., Liu C.F., Yan L., Li J.J., Wang L.J., Qi Y., et al. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol J 2012, 9(1):8.
21. Zhang W., Wang Y.G., Yang Z.H., Pang B.D., Wu H., Yang Q.Z., Jin M., Yang J.L., Li X.W., Liu Q.Q., Zhang Y.L. Severe hand-foot-and-mouth disease caused by mixed infection of enterovirus 71 and coxsackie A16: reports of 6 cases. Chin Gen Pract 2011, 29:3341-3343.
22. Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013, 381(9882):2024-2032.
23. Lee M.S., Tseng F.C., Wang J.R., Chi C.Y., Chong P., Su I.J. Challenges to licensure of enterovirus 71 vaccines. PLoS Negl Trop Dis 2012, 6(8):e1737.
24. Mao Q., Wang Y., Gao R., Shao J., Yao X., Lang S., et al. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012, 86(22):11967-11976.
25. Liu Q., Yan K., Feng Y., Huang X., Ku Z., Cai Y., et al. A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge. Vaccine 2012, 30(47):6642-6648.
26. Cai Y., Liu Q., Huang X., Li D., Ku Z., Zhang Y., et al. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection. Vaccine 2013, 31(18):2215-2221.
27. Zhao H., Li H.Y., Han J.F., Deng Y.Q., Li Y.X., Zhu S.Y., et al. Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 2013, 97(24):10445-10452.
28. Cai Y., Ku Z., Liu Q., Leng Q., Huang Z. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 2014, 32(21):2406-2412.
29. Noad R., Roy P. Virus-like particles as immunogens. Trends Microbiol 2003, 11(9):438-444.
30. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 2007, 6(3):381-390.
31. Chung Y.C., Ho M.S., Wu J.C., Chen W.J., Huang J.H., Chou S.T., et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008, 26(15):1855-1862.
32. Ku Z., Ye X., Huang X., Cai Y., Liu Q., Li Y., et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One 2013, 8(2):e57601.
33. Li H.Y., Han J.F., Qin C.F., Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013, 31(32):3281-3287.
34. Liu Q., Ku Z., Cai Y., Sun B., Leng Q., Huang Z. Detection, characterization and quantitation of coxsackievirus A16 using polyclonal antibodies against recombinant capsid subunit proteins. J Virol Methods 2011, 173(1):115-120.
35. Reed L.J.M.H. A simple method of estimating 50 percent endpoints. Am J Hyg 1938, 27:493-499.
36. Liu Q., Huang X., Ku Z., Wang T., Liu F., Cai Y., et al. Characterization of enterovirus 71 capsids using subunit protein-specific polyclonal antibodies. J Virol Methods 2013, 187(1):127-131.
37. Foo D.G., Alonso S., Phoon M.C., Ramachandran N.P., Chow V.T., Poh C.L. Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 2007, 125(1):61-68.
38. Shi J., Huang X., Liu Q., Huang Z. Identification of conserved neutralizing linear epitopes within the VP1 protein of coxsackievirus A16. Vaccine 2013, 31(17):2130-2136.
39. Feng Y.F., Liu Q.W., Ku Z.Q., Wen J.J., Shan H., Huang Z. [Expression of VP0 protein of enterovirus 71 in Escherichia coli and generation of the corresponding polyclonal antibodies in guinea pigs]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011, 27(5):535-538.
40. Ku Z., Shi J., Liu Q., Huang Z. Development of murine monoclonal antibodies with potent neutralization effects on enterovirus 71. J Virol Methods 2012, 186(1-2):193-197.
41. Ye X., Ku Z., Liu Q., Wang X., Shi J., Zhang Y., et al. Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms. J Virol 2014, 88(1):72-81.
42. Chokephaibulkit K., Perng G.C. Challenges for the formulation of a universal vaccine against dengue. Exp Biol Med (Maywood) 2013, 238(5):566-578.
43. Coller B.A., Clements D.E. Dengue vaccines: progress and challenges. Curr Opin Immunol 2011, 23(3):391-398.
44. Cao R.Y., Dong D.Y., Liu R.J., Han J.F., Wang G.C., Zhao H., et al. Human IgG subclasses against enterovirus Type 71: neutralization versus antibody dependent enhancement of infection. PLoS One 2013, 8(5):e64024.
45. Han J.F., Cao R.Y., Deng Y.Q., Tian X., Jiang T., Qin E.D., et al. Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo. Virol J 2011, 8:106.
46. Chen I.C., Wang S.M., Yu C.K., Liu C.C. Subneutralizing antibodies to enterovirus 71 induce antibody-dependent enhancement of infection in newborn mice. Med Microbiol Immunol 2013, 202(4):259-265.
47. Wang S.M., Chen I.C., Su L.Y., Huang K.J., Lei H.Y., Liu C.C. Enterovirus 71 infection of monocytes with antibody-dependent enhancement. Clin Vaccine Immunol 2010, 17(10):1517-1523.